PMPRB report reviews new drugs that may enter the Canadian market in the near future

Canada News Centre2026-04-27T14:03:24-04:00https://www.canada.ca/en/news.htmlhttps://www.canada.ca/etc/designs/canada/wet-boew/assets/wmms-blk.svgPMPRB report reviews new drugs that may enter the Canadian market in the near futurehttps://www.canada.ca/en/patented-medicine-prices-review/news/2026/04/pmprb-report-reviews-new-drugs-that-may-enter-the-canadian-market-in-the-near-future.html

Patented Medicine Prices Review Board Canada2026-04-27T14:03:24-04:00Federal Minister of Health tables the 2024 Annual Report of the Patented Medicine Prices Review Boardhttps://www.canada.ca/en/patented-medicine-prices-review/news/2025/12/federal-minister-of-health-tables-the-2024-annual-report-of-the-patented-medicine-prices-review-board.html

Sales of patented medicines in Canada were $22.1 billion in 2024, a 10.9% increase over the year before.

Patented Medicine Prices Review Board Canada2025-12-03T13:53:57-05:00Canadian public drug plan spending grew by $3.4 billion over 5 years, driven by use of higher-cost drugshttps://www.canada.ca/en/patented-medicine-prices-review/news/2025/10/canadian-public-drug-plan-spending-grew-by-34-billion-over-5-years-driven-by-use-of-higher-cost-drugs.html

The latest edition of the PMPRB CompassRx report shows that prescription drug expenditure for public drug plans grew by 7.4% in 2022/23 to reach $14.1 billion, compared to $13.2 billion in 2021/22.

Patented Medicine Prices Review Board Canada2025-10-21T15:00:59-04:00PMPRB releases new Guidelines to monitor and review drug priceshttps://www.canada.ca/en/patented-medicine-prices-review/news/2025/06/pmprb-releases-new-guidelines-to-monitor-and-review-drug-prices.html

PMPRB releases new Guidelines to monitor and review drug prices

Patented Medicine Prices Review Board Canada2025-06-30T14:00:00-04:00PMPRB report reviews potential impact of new medicines on the Canadian markethttps://www.canada.ca/en/patented-medicine-prices-review/news/2025/06/pmprb-report-reviews-potential-impact-of-new-medicines-on-the-canadian-market.html

The Patented Medicine Prices Review Board published the 9th edition of its annual Meds Entry Watch report today.

Patented Medicine Prices Review Board Canada2025-06-17T14:00:27-04:00Anie Perrault to lead PMPRB as Acting Chairpersonhttps://www.canada.ca/en/patented-medicine-prices-review/news/2025/03/anie-perrault-to-lead-pmprb-as-acting-chairperson.html

Chairperson of the PMPRB, Mr. Thomas Digby has stepped down from his role, effective March 6, 2025.

Patented Medicine Prices Review Board Canada2025-03-06T12:30:00-05:00PMPRB report shows higher-cost medicines driving a 14.1% growth in private plan drug costs in 2023https://www.canada.ca/en/patented-medicine-prices-review/news/2025/02/pmprb-report-shows-higher-cost-medicines-driving-a-141-growth-in-private-plan-drug-costs-in-2023.html

Report explores the drivers of growth in prescription drug costs for private drug plans

Patented Medicine Prices Review Board Canada2025-02-25T14:00:14-05:00Federal Minister of Health tables the 2023 Annual Report of the Patented Medicine Prices Review Boardhttps://www.canada.ca/en/patented-medicine-prices-review/news/2024/12/federal-minister-of-health-tables-the-2023-annual-report-of-the-patented-medicine-prices-review-board.html

86 new patented medicines were reported to the PMPRB in 2023

Patented Medicine Prices Review Board Canada2024-12-06T12:47:46-05:00PMPRB report reviews new drugs and their potential impact on future drug spending in Canadahttps://www.canada.ca/en/patented-medicine-prices-review/news/2024/11/pmprb-report-reviews-new-drugs-and-their-potential-impact-on-future-drug-spending-in-canada.html

The latest edition of Meds Pipeline Monitor provides stakeholders with a list of new medicines in the late stages of clinical evaluation that may significantly impact clinical practice or drug spending in the coming years.

Patented Medicine Prices Review Board Canada2024-11-05T15:00:00-05:00PMPRB report examines availability and pricing of new medicineshttps://www.canada.ca/en/patented-medicine-prices-review/news/2024/05/pmprb-report-examines-availability-and-pricing-of-new-medicines.html

The Patented Medicine Prices Review Board published the 8th edition of its annual Meds Entry Watch report today.

Patented Medicine Prices Review Board Canada2024-05-22T14:30:00-04:00Federal Minister of Health tables the 2022 Annual Report of the Patented Medicine Prices Review Boardhttps://www.canada.ca/en/patented-medicine-prices-review/news/2024/02/federal-minister-of-health-tables-the-2022-annual-report-of-the-patented-medicine-prices-review-board.html

The Honourable Mark Holland, Federal Minister of Health, today tabled the 2022 Annual Report of the Patented Medicine Prices Review Board (PMPRB) with the Clerks of the Senate and the House of Commons.

Patented Medicine Prices Review Board Canada2024-02-16T14:00:00-05:00PMPRB releases What We Learned Report from recent Policy Roundtablehttps://www.canada.ca/en/patented-medicine-prices-review/news/2024/02/pmprb-releases-what-we-learned-report-from-recent-policy-roundtable.html

The Patented Medicine Prices Review Board (PMPRB) today published its What We Learned Report, which summarizes the feedback received in the Policy Roundtable meetings it hosted in December. The report, along with the written submissions received, will help inform the PMPRB’s next steps toward developing new Guidelines.

Patented Medicine Prices Review Board Canada2024-02-15T16:00:00-05:00PMPRB release analyzes key cost pressures driving changes in public plan prescription drug expenditureshttps://www.canada.ca/en/patented-medicine-prices-review/news/2023/12/pmprb-release-analyzes-key-cost-pressures-driving-changes-in-public-plan-prescription-drug-expenditures.html

PMPRB report shows that the 10 highest-cost drugs reimbursed by public drug plans in Canada were all rare disease treatments with annual treatment costs of over $250,000.

Patented Medicine Prices Review Board Canada2023-12-12T15:00:21-05:00PMPRB announces next steps in Guidelines consultation processhttps://www.canada.ca/en/patented-medicine-prices-review/news/2023/10/pmprb-announces-next-steps-in-guidelines-consultation-process.html

The Patented Medicine Prices Review Board (PMPRB) will launch the first phase of consultations on its new Guidelines by inviting stakeholders to participate in a Policy Roundtable.

Patented Medicine Prices Review Board Canada2023-10-25T14:00:21-04:00PMPRB report reveals most new medicines come to market with high treatment costshttps://www.canada.ca/en/patented-medicine-prices-review/news/2023/08/pmprb-report-reveals-most-new-medicines-come-to-market-with-high-treatment-costs.html

The Patented Medicine Prices Review Board (PMPRB) published today the 7th edition of its annual Meds Entry Watch report.

Patented Medicine Prices Review Board Canada2023-08-22T15:00:45-04:00New report examines new drugs in the pipeline that may significantly impact future drug spending in Canada https://www.canada.ca/en/patented-medicine-prices-review/news/2023/06/new-report-examines-new-drugs-in-the-pipeline-that-may-significantly-impact-future-drug-spending-in-canada.html

Oncology continued to dominate the therapeutic mix of the drug pipeline in 2022.

Patented Medicine Prices Review Board Canada2023-06-27T15:00:00-04:00PMPRB consults on new proposed Interim Guidancehttps://www.canada.ca/en/patented-medicine-prices-review/news/2023/06/pmprb-consults-on-new-proposed-interim-guidance.html

PMPRB consults on new proposed Interim Guidance

Patented Medicine Prices Review Board Canada2023-06-20T13:30:43-04:00Spending on antidiabetic drugs in Canada outpaced overall drug market https://www.canada.ca/en/patented-medicine-prices-review/news/2023/05/spending-on-antidiabetic-drugs-in-canada-outpaced-overall-drug-market.html

Canadian prices for top-selling antidiabetic drugs were higher than those in the PMPRB’s comparator countries from 2012 to 2021.

Patented Medicine Prices Review Board Canada2023-05-30T15:00:00-04:00Patented Medicine Prices Review Board seeks applicants for vacant Board positionshttps://www.canada.ca/en/patented-medicine-prices-review/news/2023/03/patented-medicine-prices-review-board-seeks-applicants-for-vacant-board-positions.html

The Government of Canada is seeking applicants for the Vice Chairperson position and two Board Member positions on the Patented Medicine Prices Review Board by way of open, transparent, and merit-based Governor in Council selection processes.

Patented Medicine Prices Review Board Canada2023-03-10T13:00:00-05:00Douglas Clark stepping down as Executive Director of the PMPRB https://www.canada.ca/en/patented-medicine-prices-review/news/2023/02/douglas-clark-stepping-down-as-executive-director-of-the-pmprb.html

Douglas Clark, Executive Director of the Patented Medicine Prices Review Board (PMPRB), has announced that he will be stepping down from that position after almost a decade at the PMPRB.

Patented Medicine Prices Review Board Canada2023-02-24T10:00:02-05:00Increased use of higher-cost medicines continues to put pressure on Canadian public drug planshttps://www.canada.ca/en/patented-medicine-prices-review/news/2023/01/increased-use-of-higher-cost-medicines-continues-to-put-pressure-on-canadian-public-drug-plans.html

A new Patented Medicine Prices Review Board (PMPRB) report finds that prescription drug expenditures by Canadian public drug plans increased by 4.2% in 2020-21, bringing annual spending to $12.3 billion.

Patented Medicine Prices Review Board Canada2023-01-31T15:00:26-05:00Federal Minister of Health tables the 2021 Annual Report of the Patented Medicine Prices Review Boardhttps://www.canada.ca/en/patented-medicine-prices-review/news/2022/11/federal-minister-of-health-tables-the-2021-annual-report-of-the-patented-medicine-prices-review-board.html

The Honourable Jean-Yves Duclos, Federal Minister of Health, tabled the 2021 Annual Report of the Patented Medicine Prices Review Board with the Clerks of the Senate and the House of Commons on Friday.

Patented Medicine Prices Review Board Canada2022-11-21T10:48:34-05:00PMPRB Hearing Panel issues order in Procysbi casehttps://www.canada.ca/en/patented-medicine-prices-review/news/2022/11/pmprb-hearing-panel-issues-order-in-procysbi-case.html

In an order dated October 13, 2022, the Hearing Panel directed Horizon to pay $22,028,977.26 to the Receiver General of Canada within 30 days of the date of the Order. It is the largest amount ever ordered by the Board in an excessive price hearing.

Patented Medicine Prices Review Board Canada2022-11-08T15:43:19-05:00Federal drug price watchdog consulting public on proposed changes to its pricing guidelineshttps://www.canada.ca/en/patented-medicine-prices-review/news/2022/10/federal-drug-price-watchdog-consulting-public-on-proposed-changes-to-its-pricing-guidelines.html

The Patented Medicine Prices Review Board (PMPRB) released its new draft Guidelines today and launched a 60-day consultation period with stakeholders and interested members of the public.

Patented Medicine Prices Review Board Canada2022-10-06T15:30:49-04:00PMPRB Hearing Panel issues decision in Procysbi casehttps://www.canada.ca/en/patented-medicine-prices-review/news/2022/09/pmprb-hearing-panel-issues-decision-in-procysbi-case.html

A Patented Medicine Prices Review Board (PMPRB) Hearing Panel issued its decision relating to the medicine Procysbi, manufactured and marketed in Canada by Horizon Pharma.

Patented Medicine Prices Review Board Canada2022-09-28T13:30:39-04:00New report analyzes drug shortages in Canada and their impact on public drug planshttps://www.canada.ca/en/patented-medicine-prices-review/news/2022/09/new-report-analyzes-drug-shortages-in-canada-and-their-impact-on-public-drug-plans.html

The Patented Medicine Prices Review Board (PMPRB), through the National Prescription Drug Utilization Information System (NPDUIS) research initiative, today published the report Drug Shortages in Canada and their Impact on Public Drug Plans, 2017/18 to 2019/20, which provides insight into the impact of drug shortages in Canada, focusing on the effects on Canadian public drug plans and their beneficiaries.

Patented Medicine Prices Review Board Canada2022-09-21T14:36:04-04:00PMPRB Hearing Panel issues final Order in Soliris casehttps://www.canada.ca/en/patented-medicine-prices-review/news/2022/08/pmprb-hearing-panel-issues-final-order-in-soliris-case.html

A Patented Medicine Prices Review Board (PMPRB) Hearing Panel has issued an Order relating to the medicine Soliris, manufactured and marketed in Canada by Alexion Pharmaceuticals Inc.

Patented Medicine Prices Review Board Canada2022-08-02T15:42:30-04:00Market for new medicines in Canada has not slowed over last two years, despite focus on COVID-19 treatmentshttps://www.canada.ca/en/patented-medicine-prices-review/news/2022/04/market-for-new-medicines-in-canada-has-not-slowed-over-last-two-years-despite-focus-on-covid-19-treatments.html

An average of nine new medicines per quarter have been approved in Canada through the pandemic, with many more products moving through clinical trials.

Patented Medicine Prices Review Board Canada2022-04-28T13:18:14-04:00Patented Medicine Prices Review Board Imposes Deadline for Motions for Leave to Intervene in the Redetermination of Board Decisions Regarding the Excessive Pricing of Soliris Dated September 27 and November 8, 2017https://www.canada.ca/en/patented-medicine-prices-review/news/2022/04/patented-medicine-prices-review-board-imposes-deadline-for-motions-for-leave-to-intervene-in-the-redetermination-of-board-decisions-regarding-the-e.html

The Patented Medicine Prices Review Board will hold a public rehearing in the matter of the price of the patented medicine Soliris, and Alexion Pharmaceuticals Inc., the pharmaceutical company that holds the patent for Soliris and sells the medicine in Canada.

Patented Medicine Prices Review Board Canada2022-04-01T15:13:25-04:00Minister of Health tables the 2020 Annual Report of the Patented Medicine Prices Review Boardhttps://www.canada.ca/en/patented-medicine-prices-review/news/2022/03/minister-of-health-tables-the-2020-annual-report-of-the-patented-medicine-prices-review-board.html

The Honourable Jean-Yves Duclos, Federal Minister of Health, yesterday tabled the 2020 Annual Report of the Patented Medicine Prices Review Board with the Clerks of the House of Commons and the Senate.

Patented Medicine Prices Review Board Canada2022-03-31T10:07:49-04:00New PMPRB report shows significant consistency in public drug plan coverage across Canada for drugs subject to “Common Drug Review” processhttps://www.canada.ca/en/patented-medicine-prices-review/news/2022/02/new-pmprb-report-shows-significant-consistency-in-public-drug-plan-coverage-across-canada-for-drugs-subject-to-common-drug-review-process.html

The Patented Medicine Prices Review Board (PMPRB) released today the third and final part in the Alignment Among Public Formularies in Canada series, which explores the current gaps and overlaps in Canadian public drug plan formularies

Patented Medicine Prices Review Board Canada2022-02-22T11:54:41-05:00Patented Medicine Prices Review Board seeks applicants for Chairperson positionhttps://www.canada.ca/en/patented-medicine-prices-review/news/2022/01/patented-medicine-prices-review-board-seeks-applicants-for-chairperson-position.html

Patented Medicine Prices Review Board seeks applicants for Chairperson position

Patented Medicine Prices Review Board Canada2022-01-19T14:16:15-05:00Increased use of higher-cost medicines continues to put pressure on Canadian public drug plans https://www.canada.ca/en/patented-medicine-prices-review/news/2021/11/increased-use-of-higher-cost-medicines-continues-to-put-pressure-on-canadian-public-drug-plans.html

High-cost drugs accounted for over one third of total drug costs in 2019-20 but were only used by 2% of beneficiaries.

Patented Medicine Prices Review Board Canada2021-11-09T12:21:04-05:00Coverage of oncology medicines well aligned across Canadian provinces, but sources of funding differhttps://www.canada.ca/en/patented-medicine-prices-review/news/2021/05/coverage-of-oncology-medicines-well-aligned-across-canadian-provinces-but-sources-of-funding-differ.html

The Patented Medicine Prices Review Board published the second in a three part report series on Alignment Among Public Formularies in Canada

Patented Medicine Prices Review Board Canada2021-05-04T11:33:07-04:00High cost patented drugs now account for 50% of sales https://www.canada.ca/en/patented-medicine-prices-review/news/2021/03/high-cost-patented-drugs-now-account-for-50-of-sales.html

Federal Minister of Health tables the 2019 Annual Report of the Patented Medicine Prices Review Board

Patented Medicine Prices Review Board Canada2021-03-25T13:10:35-04:00New drugs entering Canada at steady rate over past 5 yearshttps://www.canada.ca/en/patented-medicine-prices-review/news/2021/02/new-drugs-entering-canada-at-steady-rate-over-past-5-years.html

Canada still among top 10 OECD countries in terms of access to new drugs

Patented Medicine Prices Review Board Canada2021-02-10T09:21:37-05:00Oncology treatments continue to dominate the drug development pipelinehttps://www.canada.ca/en/patented-medicine-prices-review/news/2021/01/oncology-treatments-continue-to-dominate-the-drug-development-pipeline.html

The latest edition of the Patented Medicine Prices Review Board (PMPRB) Meds Pipeline Monitor reports that oncology continued to dominate the therapeutic mix of the drug pipeline in 2020.

Patented Medicine Prices Review Board Canada2021-01-19T13:06:17-05:00High-cost drugs drive increased public drug plan spending in Canada https://www.canada.ca/en/patented-medicine-prices-review/news/2020/12/high-cost-drugs-drive-increased-public-drug-plan-spending-in-canada.html

Annual expenditures on drugs in public plans exceeded $12 billion in 2018-19

Patented Medicine Prices Review Board Canada2020-12-17T14:25:03-05:00Sales of cancer medicines in Canada nearly tripled over the past decadehttps://www.canada.ca/en/patented-medicine-prices-review/news/2020/10/sales-of-cancer-medicines-in-canada-nearly-tripled-over-the-past-decade.html

Today, the PMPRB, under the National Prescription Drug Utilization Information System (NPDUIS) initiative, released a chartbook on the market for oncology medicines in Canada.

Patented Medicine Prices Review Board Canada2020-10-27T14:06:13-04:00Canada’s drug price watchdog ready to apply new powers to protect Canadians from surging high cost drugs https://www.canada.ca/en/patented-medicine-prices-review/news/2020/10/canadas-drug-price-watchdog-ready-to-apply-new-powers-to-protect-canadians-from-surging-high-cost-drugs.html

PMPRB completes five year consultative process to strengthen and modernize its regime with release of new Guidelines

Patented Medicine Prices Review Board Canada2020-10-23T10:15:54-04:00